Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-03-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于公司九届二十五次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding various matters discussed at the company's 25th board meeting of the 9th session. It includes opinions on the 2019 internal control self-assessment report, 2019 profit distribution plan, 2019 annual report and summary, 2019 fundraising usage report, related party transactions, 2020 guarantee plan, appointment of the 2020 audit firm, management performance responsibility, stock repurchase related to incentive plans, extension of convertible bond issuance authorization, and nomination of a board secretary. The document is a detailed review and opinion on these corporate governance and financial matters, not the actual annual report or financial statements themselves. It is a governance-related document providing independent directors' opinions on board resolutions and company reports. The document length is 3488 characters, which is relatively short and consistent with an opinion or governance report rather than a full annual report or audit report. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on governance and management issues.
2020-03-30 Chinese
关于公司董事会秘书辞任及聘任董事会秘书的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the current company board secretary and the appointment of a new board secretary. It includes details about the qualifications of the new secretary and the approval process by the stock exchange and independent directors. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board or senior management positions. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or announcement of a report publication.
2020-03-30 Chinese
关于募集资金年度存放与实际使用情况的鉴证报告
Regulatory Filings
2020-03-30 Chinese
关于公司全资子公司昆药集团医药商业有限公司收购的部分子公司2019年度业绩承诺实现情况及处理方案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the performance fulfillment and handling plans of certain subsidiaries acquired by its wholly-owned subsidiary for the fiscal year 2019. It details the acquisition transactions, performance commitments, actual performance results, compensation clauses, and reasons for unmet performance targets. The document is a formal public announcement about the status of performance guarantees related to acquisitions, not a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis but focuses on specific performance commitments and their fulfillment status. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to acquisition performance and related financial commitments and compensations.
2020-03-30 Chinese
2019年年度报告
Annual Report Classification · 100% confidence The document is titled '2019 年年度报告' which translates to '2019 Annual Report'. It contains detailed financial data, company business overview, management discussion and analysis, financial statements, and audit information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial data, management discussion, and comprehensive company information aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification document. Therefore, the document is classified as an Annual Report (10-K). FY 2019
2020-03-30 Chinese
关于公司全资子公司昆药集团医药商业有限公司的部分子公司2019年度业绩承诺实现情况的专项审核报告
Regulatory Filings
2020-03-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.